{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:42:24Z","timestamp":1790516544716,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Excellence the Department of Pharmacy, Health and Nutritional Sciences of University of Calabria (Italy)","award":["Italian Law232\/2016"],"award-info":[{"award-number":["Italian Law232\/2016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The \u201comics revolution\u201d has totally changed the scientific research approach and is contributing to the development of personalized therapies. In motor neuron diseases (MNDs), a set of complex, multifactorial, late-onset and chronic neurodegenerative diseases, the use of multi-omics approaches in clinical trials is providing new opportunities to stratify patients and develop target therapies. To show how omics science is gaining momentum in MNDs, in this work, we review the interventional clinical trials for MNDs based on the application of omics sciences. We analyze a total of 62 clinical trials listed in the ClinicalTrials database where different omics approaches have been applied in an initial phase, for diagnosis or patient selection, or in subsequent stages to cluster subjects, identify molecular signatures or evaluate drugs security or efficacy. The rise of omics sciences in clinical experimentation of MNDs is leading to an upheaval in their diagnosis and therapy that will require significant investments and means to ensure the correct and rapid evolution of personalized medicine.<\/jats:p>","DOI":"10.3390\/jpm12050758","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T21:31:20Z","timestamp":1652045480000},"page":"758","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Advent of Omics Sciences in Clinical Trials of Motor Neuron Diseases"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6246-5901","authenticated-orcid":false,"given":"Paola","family":"Ruffo","sequence":"first","affiliation":[{"name":"Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-1792","authenticated-orcid":false,"given":"Sebastiano","family":"Cavallaro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 95126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-1783","authenticated-orcid":false,"given":"Francesca Luisa","family":"Conforti","sequence":"additional","affiliation":[{"name":"Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fneur.2018.00701","article-title":"Application of precision medicine in neurodegenerative diseases","volume":"9","author":"Strafella","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9836256","DOI":"10.1155\/2018\/9836256","article-title":"Onco-multi-omics approach: A new frontier in cancer research","volume":"2018","author":"Chakraborty","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.stem.2018.05.019","article-title":"Toward precision medicine for neurological and neuropsychiatric disorders","volume":"23","author":"Gibbs","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/B978-0-444-63916-5.00022-7","article-title":"Motor neurone disease","volume":"159","author":"Dharmadasa","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99.e7","DOI":"10.1016\/j.neurobiolaging.2020.08.017","article-title":"Genetic investigation of amyotrophic lateral sclerosis patients in south Italy: A two-decade analysis","volume":"99","author":"Ungaro","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"784996","DOI":"10.3389\/fgene.2021.784996","article-title":"Deregulation of ncRNA in neurodegenerative disease: Focus on circRNA, lncRNA and miRNA in amyotrophic lateral sclerosis","volume":"12","author":"Ruffo","year":"2021","journal-title":"Front. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s12035-017-0393-x","article-title":"Copy number variations in amyotrophic lateral sclerosis: Piecing the mosaic tiles together through a systems biology approach","volume":"55","author":"Morello","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/14737159.2020.1779060","article-title":"Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: How common are common mutations in ALS genes?","volume":"20","author":"Perrone","year":"2020","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_9","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"3","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14737175.2019.1581610","article-title":"Edaravone for the treatment of amyotrophic lateral sclerosis","volume":"19","author":"Yoshino","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2005","DOI":"10.1212\/WNL.0000000000009398","article-title":"Phenotypic variability in ALS-FTD and effect on survival","volume":"94","author":"Ahmed","year":"2020","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.molmed.2016.07.005","article-title":"Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"22","author":"Weishaupt","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gde.2017.02.008","article-title":"Relationship between C9orf72 repeat size and clinical phenotype","volume":"44","author":"Cruts","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"577755","DOI":"10.3389\/fnins.2020.577755","article-title":"From multi-omics approaches to precision medicine in amyotrophic lateral sclerosis","volume":"14","author":"Morello","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fneur.2017.00152","article-title":"Molecular Taxonomy of sporadic amyotrophic lateral sclerosis using disease-associated genes","volume":"8","author":"Morello","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1212\/WNL.0000000000004960","article-title":"Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS","volume":"90","author":"Benatar","year":"2018","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"World federation of neurology research group on motor neuron, D. El Escoriall revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Mot. Neuron. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.57.6.995","article-title":"Reversible ALS-like disorder in HIV infection","volume":"57","author":"Moulignier","year":"2001","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.12688\/f1000research.10519.1","article-title":"A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C)","volume":"6","author":"Kindy","year":"2017","journal-title":"F1000Res"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/21678421.2017.1421666","article-title":"An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis","volume":"19","author":"Fournier","year":"2018","journal-title":"Amyotroph Lateral Scler Front. Degener."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/mus.27339","article-title":"Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients","volume":"64","author":"Milligan","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","first-page":"97","article-title":"Enoxacin: A new fluoroquinolone","volume":"8","author":"Jaber","year":"1989","journal-title":"Clin. Pharm"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ana.24950","article-title":"Pyrimethamine significantly lowers cerebrospinal fluid Cu\/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations","volume":"81","author":"Lange","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000519669","article-title":"Influence of janus kinase inhibitors on the neuronal activity as a proof-of-concept model for itch","volume":"35","author":"Wohlrab","year":"2022","journal-title":"Ski. Pharm. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and its benefits for various diseases","volume":"11","author":"Lv","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ana.25520","article-title":"Presymptomatic spinal cord pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study","volume":"86","author":"Querin","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: Mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, T.H. (2020). New and developing therapies in spinal muscular atrophy: From genotype to phenotype to treatment and where do we stand?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093297"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1358\/dot.2021.57.6.3264117","article-title":"Onasemnogene abeparvovec-xioi: A gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy","volume":"57","author":"Schwartz","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: A dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Musialek, M.W., and Rybaczek, D. (2021). Hydroxyurea\u2014The good, the bad and the ugly. Genes, 12.","DOI":"10.3390\/genes12071096"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/jnnp.45.11.1012","article-title":"X-linked recessive bulbospinal neuronopathy: A report of ten cases","volume":"45","author":"Harding","year":"1982","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00415-018-8968-7","article-title":"Kennedy\u2019s disease (spinal and bulbar muscular atrophy): A clinically oriented review of a rare disease","volume":"266","author":"Breza","year":"2019","journal-title":"J. Neurol."},{"key":"ref_40","first-page":"658","article-title":"Dutasteride: A dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia","volume":"40","author":"Dolder","year":"2006","journal-title":"Ann. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(10)70321-5","article-title":"Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: A randomised placebo-controlled trial","volume":"10","author":"Kokkinis","year":"2011","journal-title":"Lancet Neurol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/5\/758\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:07:23Z","timestamp":1760137643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/5\/758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,7]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["jpm12050758"],"URL":"https:\/\/doi.org\/10.3390\/jpm12050758","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,7]]}}}